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Background: Haemophilus influenzae is the most common colonizing bacteria of the bronchial tree in chronic
obstructive pulmonary disease (COPD), and positive cultures for this potentially pathogenic microorganism (PPM)
has been associated with local inflammation changes that may influence the relationships between H. influenzae
and the bronchial mucosa.
Methods: A cross-sectional analysis of stable COPD patients enrolled in the Phenotype and Course of Chronic
Obstructive Pulmonary Disease (PAC-COPD) Study, focusing on bronchial colonization by H. influenzae, was
performed. Specific IgA against the PPM was measured by optical density, and metalloproteinase-9 (MMP-9) and
tissue inhibitor of metalloproteinase-1 (TIMP-1) using ELISA in sputum samples. Levels in patients colonized by
H. influenzae and non-colonized patients were compared.
Results: Sputum supernatant for the measurement of specific IgA against H. influenzae was available from 54 stable
COPD patients, who showed levels of specific IgA significantly lower in colonized (n=21) than in non-colonized
patients (n=33) (15 [4-37] versus 31 [10-75], p=0.033, Mann-Whitney U test). Proenzyme MMP-9 was measured in 44
patients, and it was higher in colonized (n=12, 1903 [1488-6699] ng/ml) than in non-colonized patients (n=32, 639
[373-972] ng/ml) (p<0.001, Mann-Whitney U test). Active form of MMP-9 was also higher in colonized (126 [25-277]
ng/ml) than in non-colonized patients (39 [14-68] ng/ml) (p=0.021, Mann-Whitney U test), and the molar ratio
between proenzyme MMP-9 and TIMP-1 was above 1 (2.1 [0.1-12.5]) in colonized patients, significantly higher than
the ratio found in non-colonized patients (0.2 [0.08-0.5]) (p=0.030, Mann-Whitney U test).
Conclusions: Clinically stable COPD patients colonized by H. influenzae had lower levels of specific IgA against the
microorganism and higher values of the active form of MMP-9 in their sputum supernatant than non-colonized
patients. Bronchial colonization by H. influenzae may cause structural changes in the extracellular matrix through a
defective defense and the production of active metalloproteinases.
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Potential pathogenic microorganisms (PPMs) colonize the
bronchial tree of COPD patients and are found in the bron-
chial secretions of one third of adults with stable COPD, a
rate that increases with the worsening of airflow obstruc-
tion [1]. H. influenzae is the most common colonizing bac-
teria isolated from these patients, and is also frequently
recovered when exacerbation symptoms appear [2]. This
PPM is able to adapt to changing environments through
gene expression changes [3-5], some of which modify its
virulence [6,7].
Both microorganism and host factors determine the out-
come of the acquisition of a H. influenzae strain by the
bronchial tree [8]. The bronchial mucosa is protected by a
specialized immune system focused on the prevention of
colonization and infection by PPMs, being antibodies the
first line of this defense. IgA is the principal immunoglobu-
lin produced in the bronchial tissue and a key element in
this mechanism [9,10], with a major role in host defenses
through inhibition of microbial adherence, toxin inactiva-
tion and promotion of humoral immunity [11]. The pro-
tection of bronchial mucosa from H. influenzae is partly
mediated by immune exclusion [12], an essentially mech-
anical process in which secretory IgA (sIgA) agglutinates
bacteria allowing the entrapment of the created bacterial
complexes in mucus, which are expelled through mucocili-
ary clearance. Under certain conditions H. influenzae may
produce specific enzymes that cleave human IgA1, a sub-
class of bronchial IgA, separating the antigen recognition
fragments of the immunoglobulin from its constant region
and inactivating its protective role [13-15]. This direct ef-
fect of the proteases produced by H. influenzae on the
levels of IgA may be clinically significant in the pathogen-
esis of COPD in colonized and infected patients.
The presence of H. influenzae in the bronchial tree of
stable COPD patients is associated with an inflammatory
response [16]. In colonized patients an imbalance between
endogenous proteinases and proteinase inhibitors may be
found that interferes with normal tissue function and re-
pair [17]. Matrix metalloproteinases (MMPs) are a family
of Ca2+-activated, Zn2+-dependent proteases which are
secreted by a wide variety of cells and are capable of de-
grading all components of the extracellular matrix [18].
Their activity is physiologically controlled by tissue inhibi-
tors of metalloproteinases (TIMPs), but in pathological
conditions a switch in MMP production and activity may
occur, which may lead to abnormal tissue destruction [19].
MMPs are thought to participate in the excessive collage-
nolytic and elastolytic activity found in COPD, as sug-
gested by the high levels in lung tissue and induced
sputum of patients with this disease [20-22]. Among the
MMP family, MMP-9 is responsible for tissue repair and
remodeling through the degradation of basement mem-
brane type IV collagen and other matrix proteins. TIMP-1is the major endogenous inhibitor of both MMP-8 and
MMP-9, and high levels of this protein have been found in
COPD [23].
With the hypothesis that in stable COPD bronchial
colonization by H. influenzae may be related to an
impaired local specific immunoglobulin response and to an
imbalance between MMP-9 and TIM-1 levels in bronchial
secretions, we carried out a cross-sectional analysis of spe-
cific IgA against H. influenzae and metalloproteinase activ-
ity in sputum samples recovered from patients included in
the PAC-COPD Study. Specific IgA and concentrations of
the MMP-9, both total and active, and its inhibitor TIMP-
1 were measured in sputum supernatant recovered from
stable COPD patients colonized and non-colonized by H.
influenzae. The PAC-COPD Study comprises patients who
had a first admission for COPD exacerbation and who
were examined later after the stabilization of the disease.
Methods
Design and participants
This cross-sectional analysis of the relationships between
bronchial colonization by H. influenzae in COPD, local pro-
duction of specific IgA against this PPM and metalloprotei-
nase activity is part of the population-based Phenotype and
Course of Chronic Obstructive Pulmonary Disease (PAC-
COPD) Study. The PAC-COPD Study focus on patients
who are in a moderate stage of their disease and had not
required repeated admissions when examined, and with this
purpose enrolled 342 COPD patients hospitalized for the
first time for an exacerbation of their disease in nine teach-
ing hospitals in Spain, who were evaluated later when they
were clinically stable. The recruitment process and the defi-
nitions of COPD, exacerbation and first admission in the
PAC-COPD Study have been reported elsewhere [24,25].
Stable patients from the PAC-COPD Study who expecto-
rated samples with low squamous cell content and had
complete information on sputum microbiology and inflam-
matory mediators at the baseline evaluation were identified
[26] and selected for the analysis when they presented
bronchial colonization by H. influenzae or negative sputum
cultures. Bronchial colonization by other PPMs showed
high heterogeneity and low prevalence figures (<10%) in
the PAC-COPD Study, and were excluded from the ana-
lysis. The research protocol was approved by the ethics
committees of all participating hospitals and written
informed consent was obtained from all subjects.
Clinical and functional variables
Patients were enrolled at their first hospital admission
for COPD exacerbation and answered during this admis-
sion an epidemiologic questionnaire that covered smok-
ing habits, respiratory symptoms and treatments the
previous year, performing all clinical tests at least three
months after hospital discharge and when clinically stable.
Figure 1 Ten distinct isolates of H. Influenzae, isolated from
COPD patients, used as capture antigen in ELISA testing.
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forced spirometry and reversibility testing, which were per-
formed before sputum induction. Detailed information
about the sources of the questionnaires and standardization
of the tests used in the PAC-COPD study has been pub-
lished elsewhere [24,27].
Sputum induction
Spontaneous sputum was collected for microbiology and for
measurements of specific immunity against H. influenzae
and metalloproteinase activity. In patients unable to pro-
duce sputum spontaneously a sample was induced accord-
ing to standard methods [28-30]. Patients were pre-treated
with an inhaled ß-adrenergic agent 10 minutes before neb-
ulization of increasing concentrations of saline (0.9%, 3%,
4% and 5%), for seven minutes each in order to induce spu-
tum. Patients were asked to blow their nose, rinse their
mouth, and swallow water before the procedure, and the
nebulization was interrupted when the sputum volume col-
lected was 1 ml or more [31]. After each induction the pa-
tient attempted to cough up sputum into a sterile plastic
dish. The first sputum sample was taken for the microbio-
logic exam and later sputum samples were used to analyze
inflammatory markers, specific immunity and metallopro-
teinases. Recovered sputum was processed within 60 min-
utes of collection to guarantee cell viability [32], that
was determined by trypan blue exclusion in a Neubauer
hemocytometer [24,25], and kept at 4°C when stored. Under
the assumption that samples with 20% squamous cells or
fewer were representative of tracheobronchial secretions
[33], stable patients who expectorated samples with squa-
mous cell contents below that limit were selected for the
present analysis.
Microbiology and inflammatory markers in sputum
Sputum samples were weighed, processed with an equal
volume of dithiothreitol (DTT) (Sputasol, Oxoid Ltd.,
Hants, UK), and cultured according to standard methods.
Microbiological processing included determination of mi-
crobial typology and load through serial dilutions and cul-
ture in selective media for PPMs, according to standard
methods [34] with quantitative cultures expressed as col-
ony-forming units (cfu) per milliliter. Cultures were consid-
ered positive for bronchial colonization by H.influenzae
when loads were 100 cfu/ml or higher.
Sputum was separated from contaminating saliva by
macroscopic examination. Selected sputum was mixed
with four times its weight of DTT solution and vortexed.
A weight of phosphate-buffered saline solution equal to
that of DTT was then added, and the whole mixture was
further vortexed. The suspension was filtered through
a 48-μm nylon gauze. Total inflammatory cell count,
expressed as the absolute number of cells per gram of
sputum, was calculated by subtracting squamous cellsfrom the total cell count. Absolute and differential cell
counts for neutrophils were calculated by counting 400
non-squamous cells on Wright-stained slides. The
remaining suspension was centrifuged at 750g and the
supernatant was decanted and stored at –80°C.
Cytokine concentrations (interleukin [IL] -1β, IL-6, IL-8)
were measured in the supernatant using a cytokine bead
array (BD Biosciences, San Diego CA, USA). The detection
limits of these assays were 7.2 pg/ml for IL-1β, 2.5 pg/ml
for IL-6 and 3.6 pg/ml for IL-8. All assays were performed
in duplicate and reported values correspond to the average
of the two determinations.
Specific IgA against Haemophilus influenzae in sputum
ELISA was used to determine the IgA antibody level against
H. influenzae in the supernatant of the recovered sputum
samples. The capture antigen was prepared as follows: ten
distinct isolates of H. influenzae, distinguished by different
pulsed-field gel electrophoresis patterns (Figure 1), were
grown overnight on chocolate agar plates at 37°C and 5%
CO2. Several colonies were inoculated to brain heart infu-
sion broth supplemented with 10 μg/ml of hemin and β-
nicotinamide adenine dinucleotide (NAD) (Sigma-Aldrich,
Saint Louis, Missouri) and incubated at 37°C. Bacterial
concentration was adjusted to optical density (OD) ~0.1 at
a wavelength of 625 nm (~10
8 cfu/ml) and the ten isolates
were mixed to create a pooled sample of H. influenzae
strains. Fifty μl of this suspension were used to coat each
well on a microtiter plate (Nunc Brand, Denmark) and the
plate was incubated overnight at 37°C. Between each step
the wells were washed three times with PBS (400μl/well)
and in all following steps the reagents used were added to
the wells in volumes of 100 μl. The wells were blocked by
addition of 200 μl of PBS-1% bovine serum albumin (BSA)
and incubated at 37°C for two hours. The wells were then
washed, and sputum supernatants diluted in PBS were
added and incubated for 1 h at 37°C. After washing, goat-
anti human IgA (Sigma) diluted 1:1000 in PBS-1%BSA was
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ing, anti-goat conjugated to alkaline phosphatase (Sigma)
diluted 1:5000 in PBS-1%BSA was added and incubated 1
h at 37°C. Color was developed after washing by adding a
developing buffer containing p-Nitrophenyl phosphate
(Sigma), and optical density (OD) read at 405 nm. All sam-
ples were run in triplicate and the final result was the
average of the three scores. To control for day-to-day vari-
ability, an isolate of H. influenzae and its homologous
supernatant was tested again in each plate and used as an
internal control, accepting variabilities below 15% [35].
Specific IgA determinations required the availability of a
volume equal or over 25 microliter of supernatant, and
were performed in samples from the studied patients and
in a sputum supernatant pool of nine healthy controls
from general population who were used as the normal
reference. Results were expressed as the OD ratio between
patients and the healthy control reference (OD patients-
OD pool of healthy controls/OD pool of healthy controls).
Metalloproteinase activity in sputum
Concentrations of MMP-9, both of its proenzyme of 92
kDA (proMMP-9) and its active form of 68 kDa, and of
their inhibitor TIMP-1, were determined in the sputum
supernatant using a commercially available enzyme-linked
immunosorbent assay (ELISA) kit (Amersham Biosciences,
GE Healthcare, Buckinghamshire, UK), and carried out
according to the manufacture´s recommendations. These
determinations required a volume equal or over 100 micro-
liter of supernatant, and had detection limits of 0.5 ng/ml
for MMP-9 and 3.13 ng/ml for TIMP-1.
ProMMP-9 to TIMP-1 molar ratios below 1:1 keep
MMP-9 below its activity level and are the reference in
healthy subjects [36]. Ratios above 1:1 are considered ab-
normal and are associated with availability of the active
form of MMP-9 in bronchial secretions [37].
Statistical analysis
Data were analyzed using the SPSS statistical software pack-
age version 18 (SPSS Inc., Chicago, IL, USA). Results for cat-
egorical variables are expressed as absolute and relative
frequencies, and results for continuous variables as means
and standard deviations (SD), or as medians and percentiles
25-75 (P25-P75) when the distribution was not normal.
First, clinical and functional variables and bronchial in-
flammation markers of patients showing colonization by H.
influenzae and non-colonized patients were compared, and
the difference in the specific IgA response against H. influ-
enzae in sputum found in patients colonized and non-
colonized by this PPM was assessed. The ratio between the
level of specific IgA against H. influenzae in patients and
the level in healthy subjects (OD patients-OD pool of
healthy controls/OD pool of healthy controls) was calcu-
lated in both groups and used for the comparison. Finally,the concentrations of proMMP-9, TIMP-1 and active
MMP-9 in patients colonized by H. influenzae were com-
pared with the levels found in non-colonized patients. The
molar ratio between MMP-9 and TIMP-1 was additio-
nally calculated and also used for the comparisons bet-
ween patients colonized by these PPMs and non-colonized
patients. All analyses were performed using chi-square,
Fisher exact or Mann-Whitney U tests as required. Statis-
tical tests were two-sided, and a p value of 0.05 or less was
reported as statistically significant.
Results
Sputum quality
One hundred thirty-three participants in the PAC-COPD
Study produced good quality sputum samples which
showed a low proportion of squamous cells (2 [0.5-6]) and
high cell viability (79 [64-90]), which were considered as
representative of bronchial secretions. They were COPD
patients with an average age of 70 (9) years and moderate
lung function impairment (mean post-bronchodilator forced
expiratory volume in one second [FEV1] 52% [SD 16] of
predicted) (Table 1). In 39 of these patients, PPMs were
recovered from sputum (29.3%), and in 22 (17%) of them
H. influenzae was the bacterium recovered.
Patients with bronchial colonization by H. influenzae or
negative sputum cultures were the target population for the
analysis of specific IgA (n=116), and sputum supernatant
for the measurement of specific IgA against H. influenzae
was available from 54 of these patients (46.5%), 21 colo-
nized by the PPM and 33 non-colonized, who were the
population subsample analyzed. In 44 patients sputum
availability allowed also the determination of MMP-9 and
TIMP-1 (38%), which were measured in 12 patients colo-
nized by H. influenzae and in 32 non-colonized patients
(Figure 2). The comparisons of smoking habits (pack-year),
respiratory symptoms (exacerbations in the year previous
to admission), and forced spirometry (postbronchodilator
FEV1%) in patients with specific IgA measured, in patients
who had metalloproteinase activity determined, and in
patients without sputum availability for the present analyses
(n=62) did not show statistically significant differences (data
not shown).
Clinical characteristics and bronchial inflammation
according to colonization
Clinical differences between patients colonized by H.
influenzae and non-colonized patients were not signi-
ficant, except for higher cumulative smoking in colo-
nized patients (103 [60-138] vs. 58 [36-90] pack-years;
p= 0.002) (Table 2). A similar well-defined neutrophilic
inflammatory pattern in sputum was observed in both
colonized and non-colonized patients, with significant-
ly higher median values for IL-1β (746 [121-1802] vs.
154 [41-485] pg/ml; p=0.001) and IL-8 (16 [11-22] vs. 8
Table 1 Clinical, functional and inflammatory characteristics of bronchial secretions in patients with representative
sputum samples* (n=133)
Patient characteristics
Age (years), mean (SD) 70 (9)
Males, n (%) 124 (93)
Smoking pack-years, median (P25-P75) 67 (43-102)
Current smoker, n (%) 35 (27)
Exacerbation last year ≥1, n (%) 45 (34)
FEV1 post-BD % pred, mean (SD) 52 (16)
Sputum characteristics
Neutrophils/ml ×106, median (P25-P75) 6.4 (1.7-17.1)
Neutrophils %, median (P25-P75) 72 (48-84)
IL-1β (pg/ml), median (P25-P75) 209 (52-695)
IL-6 (pg/ml), median (P25-P75) 124 (54-259)
IL-8 (×103) (pg/ml), median (P25-P75) 11 (4-16)
Colonized by PPMs, n (%) 39 (29.3)
Colonized by H. influenzae, n (%) 22 (17)
Bacterial load of H. influenzae x106 (cfu/ml), median (P25-P75) †* 5.4 (1-12)
*Patients with representative sputum samples according to percentage of squamous cells≤20%.
†* In patients with a positive culture for H. influenzae. Expressed as ×106 cfu/ml.
Definition of abbreviations: SD = standard deviation; P25-P75 = percentile 25-percentile 75; BD = bronchodilator; FEV1= forced expiratory volume in 1 second;
IL = interleukin; PPMs = potential pathogenic microorganisms; cfu = colony forming units.
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H. influenzae.
Specific IgA against H. influenzae in bronchial secretions
Level of IgA antibody against whole-cell H. influenzae
antigens in the sputum of colonized and non-colonized
patients was related to the level of IgA against this PPMFigure 2 Flow chart showing the number of subjects used in
each analysis.in the sputum samples of nine healthy controls. IgA
levels were significantly lower in patients colonized by
H. influenzae (15 [4-37]) than in non-colonized patients
(31 [10-75]) (p=0.033, Mann-Whitney U test) (Figure 3).
Sputum metalloproteinase activity
The concentration of proenzyme MMP-9 was significantly
higher in patients colonized by H. influenzae (1903 [1488-
6699] ng/ml) than in non-colonized patients (639 [373-972]
ng/ml) (p<0.001, Mann-Whitney U test) (Figure 4). No
differences were found in the levels of TIMP-1 between
these groups (Figure 5). When the level of the active form
of MMP-9 was assessed, it was also higher in patients colo-
nized by H. influenzae (126 [25-277] ng/ml) than in non-
colonized patients (39 [14-68] ng/ml), a comparison that
reached statistical significance (p=0.021, Mann-Whitney U
test) (Figure 6).
The calculation of the molar ratio between proMMP-9
and TIMP-1 showed that bronchial colonization by
H. influenzae was associated with pro MMP-9/TIMP-1
ratios above 1:1 (2.1 [0.1-12.5]), which were signifi-
cantly higher than the ratios found in non-colonized
patients (0.2 [0.08-0.5]) (p=0.030, Mann-Whitney U test)
(Figure 7).
Discussion
Sputum samples of a well-characterized cohort of stable
COPD patients who has not required repeated admissions
for exacerbation of their disease has been analyzed in the
Table 2 Patient characteristics and inflammatory mediators in sputum according to bronchial colonization by
Haemophilus influenzae (n=116)
Non-colonized Colonized by H. influenzae p value*
n=94 n=22 -
Patient characteristics
Age (years), mean (SD) 69 (9) 70 (8) 0.880
Current smoker, n (%) 24 (26) 6 (27) 0.932
Smoking pack-years, median (P25-P75) 58 (36-90) 103 (60-138) 0.002
FEV1 post-BD % pred, mean (SD) 52 (16) 50 (15) 0.597
Inhaled corticosteroids, n (%) 11 (12) 2 (9) 0.727
Inflammatory mediators in sputum
Total cells/ml × 106, median (P25-P75) 12 (4-24) 7 (4-22) 0.388
Neutrophils/ml ×106, median (P25-P75) 7 (2-18) 4 (1-14) 0.526
IL-1β (pg/ml), median (P25-P75) 154 (41-485) 746 (121-1802) <0.001
IL-6 (pg/ml), median (P25-P75) 109 (50-201) 168 (53-436) 0.172
IL-8 (×103) (pg/ml), median (P25-P75) 8 (3-15) 16 (11-22) < 0.001
*Analyses performed using chi-square, Fisher exact or Mann-Whitney U tests as required.
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by H. influenzae, the specific IgA response against this
PPM, and metalloproteinase activity in bronchial secretions
were examined. Bronchial colonization by H. influenzae
was associated with low levels of IgA against this PPM in
sputum, a defective specific immunologic response that
may difficult the eradication of H. influenzae from the
bronchial tree. Levels of proMMP-9 and its active form,
additionally, were high in patients colonized by H. influen-
zae, supporting a significant impact of this PPM on the
metalloproteinase activity in bronchial secretions, in theFigure 3 Level of specific IgA against H. influenzae in patients coloniz
Results expressed as optical density (OD) ratio between patients and healthabsence of exacerbation symptoms. These findings suggest
that bronchial colonization by H. influenzae may be related
to a defective immune response against this PPM, and asso-
ciated with an increase in MMP-9 levels to concentrations
that may cause extracellular matrix destruction and airway
remodeling.
The low levels of specific IgA against H. influenzae found
in the present study in colonized patients may be related to
protease production by the PPM or due to a defective re-
sponse of the bronchial mucosa. The immune response of
the bronchial tree is the first defense line for the protectioned by this bacteria (n=21) and non-colonized patients (n=33).
y controls.
Figure 4 Proenzyme MMP-9 concentration in the sputum supernatant of patients colonized by H. influenzae (n=12) and non-colonized
patients (n=32).
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noglobulins, functionally related to the epithelial barrier
and mucociliary clearance [38]. Secretory IgA originates
from the selective transport of polymeric IgA across the
epithelial cells, and is the predominant type of antibody in
the bronchial mucosa. This immunoglobulin agglutinates
colonizing bacteria and participates in the inhibition of bac-
terial mucosal adherence [34]. Strains of H. influenzaeFigure 5 TIMP-1 concentration in the sputum supernatant of patients
(n=32).produce IgA proteases [39,40], and levels of sIgA in bron-
chial secretions are partly influenced by the production of
specific enzymes that cleave the subtype 1 of this im-
munoglobulin (IgA1), separating the antigen recognition
fragments from the constant region of IgA, in patients
colonized by this PPM [10,14,15,41-43]. Because the first
line of the specific immunologic defense against H. influ-
enzae is provided by sIgA [9], determinants of the level ofcolonized by H. influenzae (n=12) and non-colonized patients
Figure 6 Active MMP-9 concentration in the sputum supernatant of patients colonized by H. influenzae (n=12) and non- colonized
patients (n=32).
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protease production, local consumption or defective pro-
duction may play a role in the pathogenesis of bronchial
colonization and infection in COPD [44], an hypothesis
supported by the results of the present study.
We have found high levels of the remodeling protein
proMMP-9 and its active form in stable COPD patients
colonized by H. influenzae. Previous studies have repor-
ted a relationship between bronchial colonization andFigure 7 Molar ratio between proenzyme MMP-9 and TIMP-1 in colon
non-colonized patients (n=32).inflammation in these patients, identifiable through high
levels of IL-1β and IL-8 in bronchial secretions [45-47],
with a higher effect when H. influenzae is the colonizer
[26]. Interleukin 1β, among other mediators, stimulate the
release of MMP from alveolar macrophages, and upregulate
MMP activity in the COPD airway [18]. Destruction of
small bronchi and alveoli, leading to emphysema, involves
members of the MMP family [36], and there is significant
evidence that these proteases play a significant role inized patients colonized by H. influenzae (n=12) and
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MMP-1 develop emphysema [48], whilst MMP-12 knock-
out mice are protected from emphysema despite prolonged
cigarette smoke exposure [45]. High levels of MMP-8, -9
and TIMP-1 have been found in COPD [17,49], and MMP-
9 level in bronchial secretions was higher in smokers with
COPD than in smokers without functional limitation
[50,51]. A marked increase in MMP-9 expression and activ-
ity in lung parenchyma and increased MMP-9/TIMP-1
ratios in induced sputum have been also reported in
patients with COPD, when compared with healthy subjects
[19]. Interaction with TIMPs is the physiological way to
control the proteolytic activity of MMPs in normal condi-
tions, and an imbalance between MMPs and TIMPs has
been proposed as the cause of the increased levels of
MMP-9 that are often detected in COPD patients
[23,37,49,52,53]. TIMP-1 is the major endogenous inhibitor
of MMP-8 and MMP-9, and the levels of this protein are
usually elevated in COPD [23]. As far as we know, the
present study is the first to examine the relationship be-
tween colonization by H. influenzae, MMP-9 and TIMP-1
in bronchial secretions of stable COPD patients. We have
found high levels of both proMMP-9 and its active form in
patients colonized by H. influenzae, suggesting that the
presence of H. influenzae in the airways of stable COPD
patients may have an effect on tissue matrix. The molar
ratio between proMMP-9 and TIMP-1 was also found
higher in patients colonized by H. influenzae in the
present study. ProMMP-9 to TIMP-1 ratios below 1:1
keep the metalloproteinase below its activity level and
are the reference in healthy subjects [36]. Accordingly,
values above 1:1 must be considered abnormal and asso-
ciated with availability of the active form of MMP-9 in
bronchial secretions, at levels that may be high enough
to be associated with disease [37].
Limitations of the performed study should be consid-
ered. Firstly, the present study is cross-sectional, and the
correlation between low levels of IgA and persistent or
recurrent colonization by H. influenzae cannot be con-
cluded from the available data. Secondly, the PAC-
COPD cohort included COPD patients who had mainly
moderate disease and has been hospitalized because an
exacerbation only once, and this characteristic deter-
mines that the obtained results may not be applicable to
patients with advanced COPD, who also show a higher
prevalence of bronchial colonization due to other PPMs,
which are unusual in patients with moderate disease.
The proportion of females in the PAC-COPD Study is
low, a common finding in epidemiologic studies per-
formed in Spain, attributable to the delayed introduction
of smoking habits in women in the region, and deter-
mines that the observed results may not be extrapolated
to female COPD patients. Finally, we have only analyzed
the IgA response against H. Influenzae, because otherCOPD colonizers had low figures in the PAC-COPD
Study. Therefore, further studies will be necessary to
analyze the specific immunity against other PPMs in
COPD patients.
Conclusions
In conclusion, our clinically stable COPD patients colo-
nized by H. influenzae had lower levels of specific IgA
against this microorganism and higher values of the active
form of MMP-9 in the sputum supernatant than non-
colonized patients. H. influenzae colonization may be facili-
tated by this defective specific immune response, and the
colonization by this PPM may cause structural changes in
the extracellular matrix through the stimulation of metallo-
proteinase activity.
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